SCHOLAR ROCK HOLDING CORPORATION (SRRK) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | |
| Borrowing debt due after one year | 196.20M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | 492.09M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Excluding Current Maturities |
| Total assets | 523.54M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | $196.20M | (m) | $492.09M | $523.54M | (m) |
| 2026-03-31 | (m) | (m) | (m) | $196.61M | (m) | $479.94M | $535.25M | (m) |
| 2025-12-31 | (m) | (m) | (m) | $99.71M | (m) | $367.56M | $404.27M | (m) |
| 2025-09-30 | (m) | (m) | (m) | $99.61M | (m) | $369.63M | $411.72M | (m) |
| 2025-06-30 | (m) | (m) | (m) | $49.76M | (m) | $295.01M | $340.05M | (m) |
| 2025-03-31 | (m) | (m) | (m) | $49.74M | (m) | $364.38M | $407.55M | (m) |
| 2024-12-31 | (m) | (m) | (m) | $50.15M | (m) | $437.28M | $474.92M | (m) |
| 2024-09-30 | (m) | (m) | (m) | $50.10M | (m) | $139.06M | $179.13M | (m) |
| 2024-06-30 | (m) | (m) | (m) | $48.48M | (m) | $190.49M | $226.87M | (m) |
| 2024-03-31 | (m) | (m) | (m) | $44.59M | (m) | $238.43M | $267.29M | (m) |
| 2023-12-31 | (m) | (m) | (m) | $48.68M | (m) | $279.94M | $311.04M | (m) |
| 2023-09-30 | (m) | (m) | (m) | $49.96M | (m) | $218.63M | $250.69M | (m) |
| 2023-06-30 | (m) | (m) | (m) | $49.90M | (m) | $248.73M | $284.90M | (m) |
| 2023-03-31 | (m) | (m) | (m) | $49.83M | (m) | $275.28M | $314.72M | (m) |
| 2022-12-31 | (m) | (m) | (m) | $49.74M | (m) | $315.36M | $358.17M | (m) |
| 2022-09-30 | (m) | (m) | (m) | $49.77M | (m) | $343.65M | $390.30M | (m) |
| 2022-06-30 | (m) | (m) | (m) | $38.81M | (m) | $370.69M | $424.13M | (m) |
| 2022-03-31 | (m) | (m) | (m) | $43.62M | (m) | $210.21M | $265.98M | (m) |
| 2021-12-31 | (m) | (m) | (m) | $48.42M | (m) | $252.99M | $304.44M | (m) |
| 2021-09-30 | (m) | (m) | (m) | $24.93M | (m) | $246.44M | $298.39M | (m) |
| 2021-06-30 | (m) | (m) | (m) | $24.85M | (m) | $282.22M | $332.05M | (m) |
| 2021-03-31 | (m) | (m) | (m) | $24.76M | (m) | $314.69M | $360.59M | (m) |
| 2020-12-31 | (m) | (m) | (m) | $24.68M | (m) | $341.03M | $388.31M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |